Valneva Austria Gmbh

Intercell Ag

Hookipa Biotech Gmbh

Karen Lingnau

Walter G Schmidt

Michael Buschle

Alena Egyed

Jee Loon Look

Thomas P Monath

Robert Schlegl

Michael Weber

Frank Mattner

Farshad Guirakhoo

Wolfgang Zauner

Katherine Cohen

Benjamin Wizel

Christoph Klade

Jürgen Wruss

Klaus Orlinger

Christoph Reinisch

Bettina Kiefmann

André Habel

Elizabeth Watson

Gerhard Fuhrmann

Andreas Aspöck

Robert Seid

Vera Baumgartl-Strasser

Karin Prinz

Carola Schellack

Bernhard Brim

Mario Aistleithner

Katharina Bayer

Manuela Kainer

Elsa Mühlbacher

Carola Wenander

Karin Riedl

Ursula Schlosser

Ljubomir Paucz

Christian Ruiz

Jörg Fritz

Jörge Fritz

Jürgen Frisch

Gerd Zettlmeissl

Andreas Aspock

Elsa Muhlbacher

Joerg Fritz

Thomas Monath

Andreas ASPÖCK

Elsa MÜHLBACHER

Jörg Faculty Of Medicine Department Of Immunology Fritz

Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.

CMV vaccines

Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2&#x2032; deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5&#x2032; or 3&#x2032; ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.

Methods and compositions involving immunostimulatory oligodeoxynucleotides

The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKLKLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 &#x3bc;m.

IC31 nanoparticles

The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R&#x2014;XZSZ&#x2014;XZX&#x2014;Rand an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule

1C31 nanoparticles

Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I) 

Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any X is O or S, any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2&#x2032; deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5&#x2032; or 3&#x2032; ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.

Immunostimulatory oligodeoxynucleic molecules

The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R&#x2014;XZXZ-XZX&#x2014;Rand an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

Vaccines

The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

Uses for polycationic compounds

The invention relates to a composition comprising

Antigenic composition

Growing community of inventors

Vienna, Austria

Karen Lingnau